Werewolf Therapeutics Inc
NASDAQ:HOWL

Watchlist Manager
Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc
NASDAQ:HOWL
Watchlist
Price: 1.9 USD 6.74% Market Closed
Market Cap: 84.7m USD
Have any thoughts about
Werewolf Therapeutics Inc?
Write Note

Werewolf Therapeutics Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Werewolf Therapeutics Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Werewolf Therapeutics Inc
NASDAQ:HOWL
Total Current Assets
$138.4m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Assets
$27.8B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
5%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Assets
$13.1B
CAGR 3-Years
-2%
CAGR 5-Years
-14%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Total Current Assets
$26.8B
CAGR 3-Years
3%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Assets
$9.8B
CAGR 3-Years
3%
CAGR 5-Years
15%
CAGR 10-Years
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Assets
$19.3B
CAGR 3-Years
12%
CAGR 5-Years
22%
CAGR 10-Years
24%
No Stocks Found

Werewolf Therapeutics Inc
Glance View

Market Cap
83.1m USD
Industry
Biotechnology

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The firm is focused on developing a pipeline of cancer treatments. The company is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is designed to conditionally activate molecules that stimulate both adaptive and innate immunity while addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, are intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which are used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The firm using PREDATOR platform, has developed three initial product candidates: WTX-124, WTX-330 and WTX-613.

HOWL Intrinsic Value
1.49 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Werewolf Therapeutics Inc's Total Current Assets?
Total Current Assets
138.4m USD

Based on the financial report for Dec 31, 2023, Werewolf Therapeutics Inc's Total Current Assets amounts to 138.4m USD.

What is Werewolf Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
14%

Over the last year, the Total Current Assets growth was -1%. The average annual Total Current Assets growth rates for Werewolf Therapeutics Inc have been 14% over the past three years .

Back to Top